A Study to Assess Patient-Reported Quality of Life and Effectiveness on Control of Bleeding in Adult Participants With Heavy Menstrual Bleeding Due to Uterine Fibroids Taking Oral Oriahnn Capsules

Study Identifier
P20-296
CT.gov Identifier
NCT05026502
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Other
Sign up for trial alerts

Results Available

Scientific Result Summary
Available Language(s): English
Download document(s)

Study Details

Medical Condition
  • Uterine Fibroids
    • Study Drug
    N/A
    Phase
    N/A
    Sex
    Female
    Age
    18 - 51 Years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Participants who have initiated elagolix + Estradiol/Norethindrone Acetate (E2/NETA) in the last 30 days or less, or with planned initiation of elagolix + E2/NETA prescribed as part of standard of care treatment. * Participants self-reporting heavy menstrual bleeding (HMB) associated with uterine fibroids (UF). * Participants are premenopausal (i.e., still report experiencing menses).
    Exclusion Criteria:
    * Participants that report they are pregnant or planning to become pregnant in next 6 months. * Participants reporting a surgical history of: * Hysterectomy (with or without oophorectomy). * Bilateral oophorectomy. * Participants who have initiated elagolix + E2/NETA more than 30 days ago.

    Protocol Summary

    Uterine Fibroids (UF) are noncancerous (benign) tumors that commonly occur in up to 80% of women of reproductive age. Symptoms can include heavy menstrual bleeding (HMB), low back pain, urinary frequency and urgency, gastrointestinal symptoms, and fatigue. In participants with UF, this study will prospectively assess changes in patient-reported quality of life and patient-reported effectiveness in controlling HMB when treated with elagolix, estradiol, and norethindrone acetate capsules; elagolix capsules (elagolix + E2/NETA).

    Around 200 adult premenopausal female participants in the United States with a diagnosis of HMB associated with UF and are prescribed elagolix + E2/NETA by their physicians as per standard of care will be enrolled in this direct-to-patient observational study for up to 6 months.

    Participants will have been prescribed elagolix + E2/NETA within the last 30 days prior to enrollment and will continue to take elagolix + E2/NETA throughout study participation.

    There may be a higher burden for participants in this study compared to standard of care. Electronic patient reported outcomes (ePROs) will be collected at baseline, 1, 3 and 6 months to assess the impact of Elagolix + E2/NETA on patient-reported quality of life.

    Study Locations

    Location
    Status
    Location
    IQVIA RDS, Inc.
    Durham, North Carolina, United States, 27703
    Status
    Not applicable